DESMOPRESSIN ACETATE VS VASOPRESSIN TANNATE TREATMENT OF DIABETES INSIPIDUS

醋酸去氨加压素 VS 鞣酸加压素治疗尿崩症

• 批准号: 3864007
• 负责人: CHARLES S HOLLANDER
• 金额: --
• 依托单位: NEW YORK UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3864007
• 关键词: antidiuretic; arginine vasopressin; clinical trials; diabetes insipidus; drug tolerance; human subject; human therapy evaluation; metabolism disorder chemotherapy; vasopressins

The purpose of this study will be to differentiate the effect of Desmopressin Acetate (DDAVP) versus Vasopressin Tannate (AVP) on the treatment of Diabetes Insipidus (DI). AVP has been associated with hypertension as a complication, but DDAVP has not. This is because there are two receptors postulated, a different on for each of these drugs. There are anecdotal reports of patients who are resistant to DDAVP. The investigators will differentiate the effects of these two drugs on controlling DI in five subjects.

本研究的目的是区分 醋酸去氨加压素（DDAVP）与单宁酸加压素（AVP）对 尿崩症（Diabetes Insipidus，DI）AVP与 DDAVP无高血压并发症。这是因为 是两种假定的受体，每种药物都有不同的受体。那里 是对DDAVP耐药的患者的轶事报告。的 研究人员将区分这两种药物对 在5个受试者中控制DI。